Advances in epigenetic therapeutics with focus on solid tumors

Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ning, George, Tiffany L., Otterson, Gregory A., Verschraegen, Claire, Wen, Haitao, Carbone, David, Herman, James, Bertino, Erin M., He, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056722/
https://www.ncbi.nlm.nih.gov/pubmed/33879235
http://dx.doi.org/10.1186/s13148-021-01069-7
_version_ 1783680706211217408
author Jin, Ning
George, Tiffany L.
Otterson, Gregory A.
Verschraegen, Claire
Wen, Haitao
Carbone, David
Herman, James
Bertino, Erin M.
He, Kai
author_facet Jin, Ning
George, Tiffany L.
Otterson, Gregory A.
Verschraegen, Claire
Wen, Haitao
Carbone, David
Herman, James
Bertino, Erin M.
He, Kai
author_sort Jin, Ning
collection PubMed
description Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.
format Online
Article
Text
id pubmed-8056722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80567222021-04-21 Advances in epigenetic therapeutics with focus on solid tumors Jin, Ning George, Tiffany L. Otterson, Gregory A. Verschraegen, Claire Wen, Haitao Carbone, David Herman, James Bertino, Erin M. He, Kai Clin Epigenetics Review Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors. BioMed Central 2021-04-20 /pmc/articles/PMC8056722/ /pubmed/33879235 http://dx.doi.org/10.1186/s13148-021-01069-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Jin, Ning
George, Tiffany L.
Otterson, Gregory A.
Verschraegen, Claire
Wen, Haitao
Carbone, David
Herman, James
Bertino, Erin M.
He, Kai
Advances in epigenetic therapeutics with focus on solid tumors
title Advances in epigenetic therapeutics with focus on solid tumors
title_full Advances in epigenetic therapeutics with focus on solid tumors
title_fullStr Advances in epigenetic therapeutics with focus on solid tumors
title_full_unstemmed Advances in epigenetic therapeutics with focus on solid tumors
title_short Advances in epigenetic therapeutics with focus on solid tumors
title_sort advances in epigenetic therapeutics with focus on solid tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056722/
https://www.ncbi.nlm.nih.gov/pubmed/33879235
http://dx.doi.org/10.1186/s13148-021-01069-7
work_keys_str_mv AT jinning advancesinepigenetictherapeuticswithfocusonsolidtumors
AT georgetiffanyl advancesinepigenetictherapeuticswithfocusonsolidtumors
AT ottersongregorya advancesinepigenetictherapeuticswithfocusonsolidtumors
AT verschraegenclaire advancesinepigenetictherapeuticswithfocusonsolidtumors
AT wenhaitao advancesinepigenetictherapeuticswithfocusonsolidtumors
AT carbonedavid advancesinepigenetictherapeuticswithfocusonsolidtumors
AT hermanjames advancesinepigenetictherapeuticswithfocusonsolidtumors
AT bertinoerinm advancesinepigenetictherapeuticswithfocusonsolidtumors
AT hekai advancesinepigenetictherapeuticswithfocusonsolidtumors

Ejemplares similares